Studies have indicated elevated B2M expression in prostate cancer cells, linking it to metastatic tendencies [44], and surges in serum B2M levels in multiple myeloma patients have been associated with enhanced angiogenesis and myelosuppression [45]. The gene discussed is B2M; the disease is prostate carcinoma.